ArticleFrontiers in oncology2026
Surgical resection with postoperative stereotactic radiosurgery versus stereotactic radiosurgery alone for large (>3 cm) multiple brain metastases: a propensity score-matched analysis.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: While surgery plus stereotactic radiosurgery (SRS) is established for solitary brain metastases, its role in multiple brain metastases (MBM) remains unclear. This study compared survival in MBM patients undergoing resection of the largest tumor plus postoperative SRS versus SRS alone. Methods: This retrospective study included adults with 2-4 MBM, a dominant lesion >3 cm, and Karnofsky Performance Status ≥70. We compared patients undergoing resection of the dominant lesion plus SRS against those receiving SRS alone. Propensity-score matching (PSM) balanced baseline characteristics. Overall survival (OS), progression-free survival (PFS), and prognostic factors were analyzed. Results: Of 103 patients, 16 received surgery plus SRS and 87 received SRS alone. After PSM, groups were well-balanced (median largest diameter 41.7 vs. 38.4 mm, p=0.218). Surgery plus SRS significantly improved median OS (38.9 vs. 11.6 months, p=0.013) and PFS (14.3 vs. 4.7 months, p=0.048). Multivariable regression identified surgical resection (HR 0.33, 95% CI 0.15-0.71; p=0.004), lung-cancer primary (HR 0.58, 95% CI 0.35-0.97; p=0.037), and targeted/immunotherapy (HR 0.30, 95% CI 0.18-0.51; p<0.001) as favorable prognostic factors, whereas extracranial progression predicted worse survival (HR 2.21, 95% CI 1.32-3.71; p=0.002). Conclusion: For a highly selected group of MBM patients with good performance status and a dominant mass >3 cm, resecting the largest tumor followed by SRS may be associated with improved OS and PFS compared to SRS alone. Prospective studies are needed to validate these preliminary findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.